Movi Health Llc Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Movi Health Llc Pharmaceutical Import Records from India — 2 Products, $1.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Movi Health Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $1.7M Trade | TransData Nexus

Movi Health Llc

Pharmaceutical Importer · Poland · Nutritional Supplements Focus · $1.7M Total Trade · DGFT Verified

Movi Health Llc is a pharmaceutical importer based in Poland with a total trade value of $1.7M across 2 products in 2 therapeutic categories. Based on 47 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Movi Health Llc sources from 1 verified Indian supplier, with Sava Healthcare Limited accounting for 100.0% of imports.

Movi Health Llc — Import Portfolio & Supplier Network

Movi Health Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Movi Health Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sava Healthcare Limited	$6.9M	375	100.0%

Movi Health Llc sources from 1 verified Indian supplier across 173 distinct formulations. The sourcing is highly concentrated — Sava Healthcare Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Movi Health Llc Import?

Formulation	Value	Ships
Movex comfort,coated tablets	$463.6K	24
Movex active,coated tablets	$289.0K	15
Movex comfort,coated tablets	$283.6K	13
Movex comfortcoated tablets	$200.6K	9
Movex comfort, coated tablets	$181.3K	9
Movex active,coated tablets	$163.8K	9
Pulmobreath,coated tablets n20 (20x1)	$153.1K	9
Movex active coated tablets	$123.0K	6
Helpex anticold dxtablets n100 10 x	$119.0K	8
Helpex anticold dx, tablets n100 (10 x 10) Each uncoated tablet contains paracetamol BP 500 MG as per	$114.9K	4
Movex active, coated tablets	$114.9K	6
Movex activecoated tablets	$108.7K	6
Helpex anticold,tablets n100 (10x10)	$105.8K	6
Pulmobreathe,coated tablets n20 (20x1)	$100.8K	7
Pulmobreathcoated tablets n.20	$95.2K	5

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Glucosamine	Nutritional Supplements	$868.3K	24	6.6%	5
2	Ambroxol	Respiratory & OTC	$818.9K	23	5.5%	4

Movi Health Llc imports 2 pharmaceutical products across 2 categories into Poland totaling $1.7M.

Movi Health Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Movi Health Llc is a pharmaceutical importer based in Poland, specializing in the acquisition of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company plays a pivotal role in Poland's pharmaceutical distribution network, sourcing a diverse range of medicinal products to meet the country's healthcare needs. While specific details about its parent company are not publicly available, Movi Health Llc's operations are integral to the Polish pharmaceutical supply chain, ensuring the availability of essential medications across the nation.

2Distribution Network

Movi Health Llc's distribution network encompasses multiple warehouse locations strategically situated to facilitate efficient logistics and timely delivery of pharmaceutical products throughout Poland. The company's logistics capabilities are robust, enabling it to manage a diverse portfolio of medicinal products and maintain a steady supply to meet market demands. While the primary focus is on the domestic market, Movi Health Llc's operations may extend to neighboring countries, leveraging Poland's central location within Europe to serve a broader regional market.

3Industry Role

In Poland's pharmaceutical supply chain, Movi Health Llc functions as a primary wholesaler and importer. The company is responsible for sourcing and distributing a wide array of pharmaceutical products, ensuring that both prescription and over-the-counter medications are accessible to healthcare providers and patients across the country. By importing finished pharmaceutical formulations, Movi Health Llc bridges the gap between international manufacturers and the Polish market, contributing to the overall efficiency and effectiveness of the nation's healthcare system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Movi Health Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Movi Health Llc demonstrates a high degree of supplier concentration, with all its pharmaceutical imports originating from a single supplier, SAVA Healthcare Limited. This exclusive sourcing strategy indicates a deep-rooted partnership, potentially offering benefits such as favorable pricing, consistent product quality, and streamlined logistics. However, this dependency also introduces risks; any disruptions in SAVA Healthcare Limited's operations—be it due to regulatory issues, production challenges, or geopolitical factors—could significantly impact Movi Health Llc's ability to meet market demands. The absence of alternative suppliers may limit the company's flexibility in responding to such disruptions, underscoring the importance of robust contingency planning and continuous monitoring of the supply chain.

2Supply Chain Resilience

The resilience of Movi Health Llc's supply chain is closely tied to the stability and reliability of SAVA Healthcare Limited. Given the exclusive nature of their partnership, Movi Health Llc's ability to diversify its supplier base is limited, potentially exposing the company to supply chain vulnerabilities. To mitigate these risks, it is essential for Movi Health Llc to establish contingency plans, such as identifying alternative suppliers and maintaining strategic stock levels. Additionally, ensuring that SAVA Healthcare Limited adheres to international Good Manufacturing Practice (GMP) standards is crucial for maintaining product quality and compliance with regulatory requirements. Regular audits and assessments of SAVA Healthcare Limited's operations can help identify potential issues proactively, allowing Movi Health Llc to take corrective actions before disruptions occur.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (Główny Inspektorat Farmaceutyczny, GIF) is the primary regulatory authority overseeing the manufacturing and import of medicinal products. Under the Pharmaceutical Law Act, entities involved in the manufacture or import of medicinal products must obtain authorization from the Chief Pharmaceutical Inspector. This regulatory framework ensures that all pharmaceutical products meet the required quality, safety, and efficacy standards before entering the Polish market. The GIF conducts regular inspections to verify compliance with Good Manufacturing Practice (GMP) requirements, thereby safeguarding public health and maintaining the integrity of the pharmaceutical supply chain. (archiwum.gif.gov.pl)

2Import Licensing & GMP

Importing medicinal products into Poland necessitates obtaining a license from the Chief Pharmaceutical Inspectorate. This license is granted based on the applicant's compliance with GMP standards, which are aligned with European Union regulations. For Indian exporters, it is imperative to ensure that their manufacturing facilities are certified under EU GMP or WHO GMP standards to meet Polish import requirements. Additionally, obtaining wholesale distribution authorization is essential for entities involved in the distribution of medicinal products within Poland. This comprehensive regulatory framework aims to maintain high standards of pharmaceutical quality and safety in the Polish market. (archiwum.gif.gov.pl)

Movi Health Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Movi Health Llc's focus on importing nutritional supplements and respiratory over-the-counter (OTC) medications aligns with prevailing health trends and consumer demand in Poland. The significant import value of glucosamine and ambroxol indicates a strong market preference for products addressing joint health and respiratory conditions. This strategic product selection suggests that Movi Health Llc is attuned to the therapeutic needs of the Polish population, positioning itself as a key supplier of essential health products.

2Sourcing Profile

Movi Health Llc's sourcing strategy is centered on obtaining finished pharmaceutical formulations from a single supplier, SAVA Healthcare Limited. This approach allows for streamlined procurement processes and potentially favorable terms. However, the lack of diversification in sourcing may expose the company to risks associated with supplier-specific issues. To mitigate these risks, it would be prudent for Movi Health Llc to explore additional suppliers, particularly those offering complementary products or formulations, thereby enhancing the resilience and diversity of its product portfolio.

3Market Positioning

Seller's Guide — How to Become a Supplier to Movi Health Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Movi Health Llc, especially in areas where the company seeks to diversify its product offerings or enhance supply chain resilience. Identifying gaps in Movi Health Llc's current sourcing, such as the need for alternative suppliers or additional product lines, can provide entry points for Indian exporters. By offering high-quality, GMP-compliant products that align with Movi Health Llc's strategic focus, Indian suppliers can establish mutually beneficial partnerships, thereby expanding their market presence in Poland.

2Requirements & Qualifications

Indian exporters aiming to supply Movi Health Llc must ensure that their manufacturing facilities are certified under EU GMP or WHO GMP standards. Additionally, obtaining wholesale distribution authorization from the Chief Pharmaceutical Inspectorate is essential for legal compliance in Poland. Products must undergo batch testing and meet stability requirements, with labeling in Polish and adherence to serialization mandates. Ensuring compliance with these regulatory standards is crucial for successful market entry and sustained business operations in Poland.

How to Approach

Frequently Asked Questions — Movi Health Llc

What products does Movi Health Llc import from India?

Movi Health Llc imports 2 pharmaceutical products across 2 categories. Top imports: Glucosamine ($868.3K), Ambroxol ($818.9K).

Who supplies pharmaceuticals to Movi Health Llc from India?

Movi Health Llc sources from 1 verified Indian suppliers. The primary supplier is Sava Healthcare Limited (100.0% of imports, $6.9M).

What is Movi Health Llc's total pharmaceutical import value?

Movi Health Llc's total pharmaceutical import value from India is $1.7M, based on 47 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Movi Health Llc focus on?

Movi Health Llc imports across 2 categories. The largest: Nutritional Supplements (51.5%), Respiratory & OTC (48.5%).

Get Full Movi Health Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.